Thomas Michael Perone
Known title: General Counsel, SecretaryCIK: 0001771761
Associated companies
Transaction History
| OVID | ▲ Buy | Grant | 28,125 | $0 | 2/22/2024 | View on chart |
| OVID | ▲ Buy | Grant | 28,125 | $0 | 2/22/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Ovid Therapeutics shares decline in pre-market session
Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.
Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.